Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 77 results for vitamin d

  1. How can a multiagency approach to improving awareness, availability and uptake of vitamin D supplements best be established, improved and sustained?

    multiagency approach to improving awareness, availability and uptake of vitamin D supplements best be established, improved and...

  2. Dietary supplements:- Should people with coeliac disease be offered calcium and vitamin D supplements for a specific time period soon after their initial diagnosis?

    supplements:- Should people with coeliac disease be offered calcium and vitamin D supplements for a specific time period soon after...

  3. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  4. What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

    NG191/19 Question What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?...

  5. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Recommendation ID CG186/5 Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory

  6. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

    Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.

  7. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

  8. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

  9. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

  10. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  11. Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)

    This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.

  12. What is the clinical utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism?

    explanatory notes(if applicable) Measuring vitamin D No evidence was available on measuring vitamin D to assess primary...

  13. COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)

    This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).